I-MAB (IMAB) Total Liabilities : $125.32 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Total Liabilities?

I-MAB's Total Liabilities for the quarter that ended in Dec. 2023 was $125.32 Mil.

I-MAB's quarterly Total Liabilities declined from Dec. 2022 ($166.93 Mil) to Jun. 2023 ($148.70 Mil) and declined from Jun. 2023 ($148.70 Mil) to Dec. 2023 ($125.32 Mil).

I-MAB's annual Total Liabilities increased from Dec. 2021 ($163.54 Mil) to Dec. 2022 ($166.93 Mil) but then declined from Dec. 2022 ($166.93 Mil) to Dec. 2023 ($125.32 Mil).

I-MAB Total Liabilities Historical Data

The historical data trend for I-MAB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Total Liabilities Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

537.84

108.06

163.54

166.93

125.32

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial								163.54	145.70	166.93	148.70	125.32

I-MAB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

I-MAB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.675	+	(11.486	+	13.741
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	42.418	+	0)
	=	125.32

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	365.952	-	240.631
	=	125.32

I-MAB's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.675	+	(11.486	+	13.741
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	42.418	+	0)
	=	125.32

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	365.952	-	240.631
	=	125.32

I-MAB Total Liabilities Related Terms

Thank you for viewing the detailed overview of I-MAB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.